The quality of pharmacoeconomic evaluations of age-related macular degeneration therapeutics: a systematic review and quantitative appraisal of the evidence.
OBJECTIVE
To appraise the quality of published pharmacoeconomic studies of therapeutic interventions for age-related macular degeneration (AMD).


METHODS
Systematic review of the literature and evaluation of study quality using the Quality of Health Economic Studies instrument. A systematic search of the English-language literature for economic studies of therapeutic interventions for AMD from 1990 to March 2008 was performed.


RESULTS
A total of 3637 articles were initially identified. Only 24 met eligibility criteria and were rated using the Quality of Health Economic Studies. The mean quality overall rating was 61.6, with quality scores ranging from 18 to 92. There was a higher mean quality score in the studies designed as clinical trials versus observational type designed studies (mean=74.7(11.4), 52.6 (16.5) respectively, p=0.002) and studies in which the statistical analyses were clearly presented versus studies in which the statistical analyses were not so clear (mean=74.3 (12.3), 53.1 (16.1) respectively, p=0.004). Interestingly, government funded studies exhibited a similar mean quality score to studies that were funded by industry (mean=71.0 (15.1), 61.7 (18.5) respectively, p=0.25). A general linear model was fitted using those independent variables which were significantly associated with quality score. The variables 'study design' and 'statistics presented clearly' were found to be jointly significant and explained nearly 70% of the variation in the dependent variable (R(2)=0.68).


CONCLUSIONS
Our analysis reveals that the methodological quality of the health economic analysis of AMD therapeutic interventions in the literature is suboptimal. There is considerable variation in methodological rigour between the articles, and we have identified several attributes that are predictive of study quality.
Foster
William J
WJ
Ophthalmic Research and Nanotechnology Group, Department of Physics, University of Houston, TX 77030, USA.
Tufail
Waqas
W
Issa
Amalia M
AM
D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D006801:Humans; D008028:Light Coagulation / Q000191:economics*; D008268:Macular Degeneration / Q000188:drug therapy* / Q000191:economics / Q000601:surgery; D010778:Photochemotherapy / Q000191:economics*
D020533:Angiogenesis Inhibitors
Ophthalmology. 1994 Sep;101(9):1522-8
8090455
Ophthalmology. 2007 Jul;114(7):1319-26
17320962
Am J Ophthalmol. 2006 Dec;142(6):1076-9
17157601
Pharmacoeconomics. 1996 Jun;9(6):535-59
10160481
J Am Geriatr Soc. 2001 May;49(5):508-15
11380741
Int J Technol Assess Health Care. 2008 Summer;24(3):318-25
18601800
Am J Epidemiol. 2000 Oct 1;152(7):633-9
11032158
JAMA. 2000 Apr 19;283(15):2008-12
10789670
Br J Ophthalmol. 2007 Sep;91(9):1244-6
17431015
Phys Ther. 2009 Aug;89(8):733-55
19556332
Br J Ophthalmol. 2004 Aug;88(8):982-7
15258009
J Fr Ophtalmol. 2007 Oct;30(8):837-41
17978682
Ophthalmology. 2007 Feb;114(2):253-62
17270675
Ophthalmology. 2002 Oct;109(10):1767-79
12359593
Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2237-41
11527936
Arch Ophthalmol. 1984 Nov;102(11):1640-2
6208888
J Manag Care Pharm. 2003 Jan-Feb;9(1):53-61
14613362
Ophthalmic Epidemiol. 2004 Dec;11(5):337-46
15590581
Health Technol Assess. 2003;7(9):v-vi, 1-98
12709292
Eye (Lond). 2007 Dec;21(12):1455-63
17086167
Br J Ophthalmol. 2004 Apr;88(4):450-4
15031152
BMJ. 1996 Aug 3;313(7052):275-83
8704542
CMAJ. 2007 Jan 16;176(2):199-205
17179219
J Am Geriatr Soc. 1998 Jan;46(1):58-64
9434666
Med Care. 2003 Jan;41(1):32-44
12544542
Arch Soc Esp Oftalmol. 2006 Apr;81(4):199-204
16688643
JAMA. 1997 May 21;277(19):1552-7
9153371
Arch Ophthalmol. 1993 Sep;111(9):1189-99
7689826
Value Health. 2008 May-Jun;11(3):435-9
18489667
Semin Ophthalmol. 2001 Dec;16(4):218-22
15513444
Ophthalmology. 2001 Nov;108(11):2051-9
11713079
Br J Ophthalmol. 2004 Sep;88(9):1107-12
15317697
Ophthalmology. 2004 May;111(5):857-62
15121359
Can J Ophthalmol. 2005 Jun;40(3):369-77
15947806
Genet Med. 2005 Oct;7(8):519-23
16247290
Ophthalmology. 2008 Oct;115(10):1735-41
18439679
Ophthalmology. 1997 Jan;104(1):7-21
9022098
Ophthalmology. 2007 Jun;114(6):1170-8
17320964
Arch Ophthalmol. 1997 Jun;115(6):741-7
9194725
Ophthalmology. 2003 Apr;110(4):644-50
12689880
Clin Exp Ophthalmol. 2000 Aug;28(4):268-73
11021555
Arch Ophthalmol. 1995 Mar;113(3):301-8
7534060
JAMA. 1997 Jun 11;277(22):1802-6
9178794
Gastroenterology. 2004 Aug;127(2):403-11
15300571
Am J Ophthalmol. 2005 Oct;140(4):679-87
16226519
Retina. 2003 Jun;23(3):279-87; ; quiz 443-4
12824826
Technol Eval Cent Assess Program Exec Summ. 2005 Dec;20(11):1-2
16489722
Arch Ophthalmol. 2002 Oct;120(10):1357-63
12365915
Pharmacoeconomics. 2007;25(10):863-79
17887807